Sabina Berlin
CFO
Replay available
Devyser Diagnostics AB (publ) (DVYSR) Q2 2026 Earnings Call
Devyser Diagnostics AB (publ) (STO: DVYSR) Q2 2026 earnings conference call, held 2026-07-20. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Arvid Niekader
Analyst, DNB Carnegie
Jan Wallström
CEO
Eric Carlson
Analyst, Capeview
Philip Weiberg
Analyst, Pareto Securities
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Devyser Diagnostics Ab.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.835 Welcome to Divisor Diagnostics Q2 Report 2026 presentation. 00:00:04.835 -- 00:00:10.138 During the Q&A session, participants are able to ask questions by dialing pound key 00:00:10.138 -- 00:00:14.922 5 on their telephone keypad. Now, I will hand the conference over to the speakers. 00:00:14.922 -- 00:00:20.645 CEO Jan Wallstrom and CFO Sabina Berlin, please go ahead. 00:00:21.317 -- 00:00:26.161 Good morning and welcome to Devizor's Q2 2026 earnings call. 00:00:26.161 -- 00:00:30.926 I'm Jan Wallström, CEO of Devizor and would like to thank you everyone for joining our 00:00:30.926 -- 00:00:33.246 call today. 00:00:33.708 -- 00:00:39.273 On the call today we have in addition to myself also our CFO Sabina Berlin. 00:00:39.273 -- 00:00:42.676 I will start with a short summary of highlights for the quarter before handing over to 00:00:42.676 -- 00:00:47.095 Sabina for a more detailed review of our financial results. 00:00:47.095 -- 00:00:53.316 for April to June and then we'll go through an update on our recent commercial activities. 00:00:55.437 -- 00:00:59.978 Second quarter had a setback in sales due to lower than expected sales to our biggest 00:00:59.978 -- 00:01:02.618 distributor. However, 00:01:02.618 -- 00:01:08.500 despite this, we had positive EBIT earning for the fifth consecutive quarter 00:01:08.500 -- 00:01:12.920 and for the first half year improved profitability 00:01:13.661 -- 00:01:16.721 when we had flat sales. 00:01:18.799 -- 00:01:23.400 In the second quarter of the year, we had weak sales in transplant products, as I said, 00:01:23.400 -- 00:01:29.002 as lab onboarding has taken more time and the volume buildup is therefore delayed. 00:01:29.002 -- 00:01:35.403 The underlying growth the last year has been real...